Xeris Biopharma Holdings, INC 8-K filings

Xeris Biopharma announced robust second quarter 2026 financial results, featuring a 34% year-over-year increase in net product revenue driven by Recorlev, and tightened its full-year revenue guidance.

Xeris Biopharma Holdings, Inc. has concluded privately negotiated exchange transactions and a note conversion, resulting in the retirement of all outstanding 8.00% Convertible Senior Notes due 2028.

Xeris Biopharma Holdings, Inc. announced a private exchange of approximately $23 million in convertible notes for cash and company stock, reducing debt and annual interest payments.

Xeris Biopharma Holdings, Inc. successfully concluded its 2026 Annual Meeting with the election of directors and ratification of its auditor.

Xeris Biopharma announced a 43% year-over-year increase in total product revenue for Q1 2026, reaching over $82 million, and tightened its full-year revenue guidance.

Xeris Biopharma Holdings, Inc. announced that director Dr. Jeffrey Sherman will retire from the Board at the 2026 Annual Meeting.

Xeris Biopharma delivered record Q4 and full-year 2025 revenue, turned profitable, and guided 2026 revenue to $375–$390 million with higher investment in XP-8121 and Recorlev.

Xeris Biopharma subsidiaries have filed a patent infringement lawsuit against two generic drug companies to protect its Recorlev intellectual property until 2040.

Xeris Biopharma Holdings, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, expecting record total revenue of $292 million, surpassing its guidance.

Xeris Biopharma announced a Notice of Allowance from the USPTO for its XP-8121 patent application, strengthening IP for its hypothyroidism treatment candidate.

Xeris Biopharma Holdings, Inc. announced record third-quarter 2025 financial results, with total product revenue up 40% year-over-year, and updated its full-year 2025 revenue guidance.

Xeris Biopharma Holdings, Inc. announced record second-quarter 2025 financial results, with total revenue up 49% year-over-year, and raised its full-year 2025 revenue guidance.

Xeris Biopharma Holdings, Inc. announced the successful passage of all proposals at its 2025 Annual Meeting of Stockholders, including the election of Class I directors, ratification of its independent auditor, and approval of executive compensation.

Xeris Biopharma Holdings, Inc. outlined its long-term strategic vision and financial outlook at its first Analyst and Investor Day, projecting significant revenue growth driven by Recorlev and the pipeline asset XP-8121.

Xeris Biopharma announced a 48% year-over-year increase in total revenue to over $60 million for the first quarter of 2025, driven by strong growth in Recorlev sales.

Xeris Biopharma Holdings, Inc. announces the resignation of Ricki Fairley, the retirement of John Schmid, and the appointment of James Brady to its Board of Directors.

Xeris Biopharma reports record quarterly and full-year revenue, driven by strong product performance, and anticipates continued growth in 2025.

Xeris Biopharma Holdings announces the appointment of Dr. Anh Nguyen as Chief Medical Officer, succeeding Ken Johnson, who will retire on April 1, 2025.

Xeris Biopharma expects to surpass its full-year 2024 revenue guidance, reaching $203 million and anticipates a year-end cash position of over $71 million with positive cash flow in the fourth quarter.

Xeris Biopharma reported record total revenue of $54.3 million in the third quarter of 2024, driven by strong product sales, and raised its full-year revenue guidance.

Xeris Biopharma announced a strong second quarter with record product revenue, leading to tightened full-year revenue and cash guidance.

Xeris Biopharma Holdings, Inc. has promoted Kevin McCulloch to President and Chief Operating Officer, effective August 1, 2024, with a new employment agreement including a base salary of $520,000 and significant equity grants.

Xeris Biopharma announced a CEO succession plan with John Shannon succeeding Paul Edick, and preliminary Q2 2024 revenue exceeding $47 million, representing over 23% growth year-over-year.

Xeris Biopharma's shareholders approved an amendment to the employee stock purchase plan, removing the evergreen provision and increasing the share pool by 6,636,632 shares.

Xeris Biopharma announced a 22% increase in total revenue for the first quarter of 2024, reaching $40.6 million, and tightened its full-year revenue guidance to $175-$200 million.

Xeris Biopharma refinanced its debt, securing $215 million in new capital and reported a 49% increase in full-year revenue for 2023.